Amyotrophic Lateral Sclerosis | Epidemiology | Mature Markets Data

Publish date: May 2018

Login to access report

DRG Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of ALS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for other countries.

DRG Epidemiology’s ALS forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALS over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following ALS subpopulations:

  • Diagnosed prevalent cases by comorbidity status.
  • Diagnosed prevalent cases by subtype status.

Note: Coverage may vary by country.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
      • Prevalence of Amyotrophic Lateral Sclerosis per 100,000 Among Adults in 2018 and 2038
      • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Amyotrophic Lateral Sclerosis over the Next 20 Years
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases (Definite)
      • Diagnosed Incident Cases (Definite + Probable)
      • Diagnosed Prevalent Cases (Definite)
      • Diagnosed Prevalent Cases (Definite + Probable)
      • Subtype Cases
      • Diagnosed Prevalent Cases by Comorbidity
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Swarali Tadwalkar, MPH; Nishant Kumar, MPH

Swarali joined Decision Resources Group (DRG) in 2016 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with her particular interests in the oncology space. Prior to joining DRG, she has been extensively involved in primary and secondary healthcare research. Her experience involves projects in digital health, health policy and management, and health economics and outcomes research (HEOR). She has also coordinated various non-governmental public health projects focusing in hepatitis and human papilloma virus treatment access. Swarali holds a Masters in Public Health (Epidemiology) degree from the University of South Florida, Tampa.

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.